{"id":"NCT03245008","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain","officialTitle":"A Phase 2/3 (Placebo-Controlled, Double-Blind, Comparative) Study on MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-09-08","primaryCompletion":"2019-12-14","completion":"2021-03-09","firstPosted":"2017-08-10","resultsPosted":"2023-05-17","lastUpdate":"2023-05-17"},"enrollment":626,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis, Knee / Osteoarthritis, Hip"],"interventions":[{"type":"DRUG","name":"MT-5547","otherNames":["Fasinumab"]},{"type":"DRUG","name":"MT-5547-matching placebo","otherNames":[]}],"arms":[{"label":"MT-5547 dosing regimen 1","type":"EXPERIMENTAL"},{"label":"MT-5547 dosing regimen 2","type":"EXPERIMENTAL"},{"label":"MT-5547-matching placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to verify the superiority of 16 weeks of MT-5547 treatment to placebo, as evidenced by the WOMAC pain score (the efficacy outcome measure), in patients with osteoarthritis of the knee or hip. Additional objectives of the study are to investigate the efficacy, safety, and pharmacokinetics of MT-5547 in long-term use.","primaryOutcome":{"measure":"WOMAC Pain Score (Change From Baseline at Week 16)","timeFrame":"Baseline to Week 16","effectByArm":[{"arm":"Pooled Placebo","deltaMin":-1.74,"sd":0.17},{"arm":"Pooled MT-5547 1 mg q4w","deltaMin":-2.96,"sd":0.17},{"arm":"After the Amendment Placebo","deltaMin":-1.78,"sd":0.18},{"arm":"After the Amendment MT-5547 1 mg q8w","deltaMin":-2.12,"sd":0.18},{"arm":"After the Amendment MT-5547 1 mg q4w","deltaMin":-2.79,"sd":0.18}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG002 vs OG003","p":"0.103"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":18},"locations":{"siteCount":27,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":204},"commonTop":["Nasopharyngitis","Back pain","Headache","Rapidly progressive osteoarthritis","Arthralgia"]}}